The ORR keeps going down to 42%. In the past folfox chemotherapy has achieved 50% in KRAS CRC but eventually failed later. The market expects more. Well this is a known hazard of biotech investing where further trial result disappoints.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.